CRL Relative Valuation
CRL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CRL is overvalued; if below, it's undervalued.
Historical Valuation
Charles River Laboratories International Inc (CRL) is now in the Fair zone, suggesting that its current forward PE ratio of 17.57 is considered Fairly compared with the five-year average of 22.54. The fair price of Charles River Laboratories International Inc (CRL) is between 171.88 to 284.65 according to relative valuation methord.
Relative Value
Fair Zone
171.88-284.65
Current Price：184.67
Fair
17.51
PE
1Y
3Y
5Y
Trailing
Forward
11.83
EV/EBITDA
Charles River Laboratories International Inc. (CRL) has a current EV/EBITDA of 11.83. The 5-year average EV/EBITDA is 15.07. The thresholds are as follows: Strongly Undervalued below 7.04, Undervalued between 7.04 and 11.06, Fairly Valued between 19.08 and 11.06, Overvalued between 19.08 and 23.10, and Strongly Overvalued above 23.10. The current Forward EV/EBITDA of 11.83 falls within the Historic Trend Line -Fairly Valued range.
14.45
EV/EBIT
Charles River Laboratories International Inc. (CRL) has a current EV/EBIT of 14.45. The 5-year average EV/EBIT is 18.27. The thresholds are as follows: Strongly Undervalued below 9.15, Undervalued between 9.15 and 13.71, Fairly Valued between 22.83 and 13.71, Overvalued between 22.83 and 27.39, and Strongly Overvalued above 27.39. The current Forward EV/EBIT of 14.45 falls within the Historic Trend Line -Fairly Valued range.
2.25
PS
Charles River Laboratories International Inc. (CRL) has a current PS of 2.25. The 5-year average PS is 3.08. The thresholds are as follows: Strongly Undervalued below 0.97, Undervalued between 0.97 and 2.02, Fairly Valued between 4.13 and 2.02, Overvalued between 4.13 and 5.18, and Strongly Overvalued above 5.18. The current Forward PS of 2.25 falls within the Historic Trend Line -Fairly Valued range.
15.37
P/OCF
Charles River Laboratories International Inc. (CRL) has a current P/OCF of 15.37. The 5-year average P/OCF is 17.33. The thresholds are as follows: Strongly Undervalued below 6.98, Undervalued between 6.98 and 12.15, Fairly Valued between 22.51 and 12.15, Overvalued between 22.51 and 27.68, and Strongly Overvalued above 27.68. The current Forward P/OCF of 15.37 falls within the Historic Trend Line -Fairly Valued range.
18.57
P/FCF
Charles River Laboratories International Inc. (CRL) has a current P/FCF of 18.57. The 5-year average P/FCF is 28.07. The thresholds are as follows: Strongly Undervalued below 11.54, Undervalued between 11.54 and 19.80, Fairly Valued between 36.33 and 19.80, Overvalued between 36.33 and 44.59, and Strongly Overvalued above 44.59. The current Forward P/FCF of 18.57 falls within the Undervalued range.
Charles River Laboratories International Inc (CRL) has a current Price-to-Book (P/B) ratio of 2.67. Compared to its 3-year average P/B ratio of 2.95 , the current P/B ratio is approximately -9.55% higher. Relative to its 5-year average P/B ratio of 4.34, the current P/B ratio is about -38.52% higher. Charles River Laboratories International Inc (CRL) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 4.59%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 3.89% , the current FCF yield is about -100.00% lower.
2.66
P/B
Median3y
2.95
Median5y
4.34
5.98
FCF Yield
Median3y
4.59
Median5y
3.89
Competitors Valuation Multiple
The average P/S ratio for CRL's competitors is 1.99, providing a benchmark for relative valuation. Charles River Laboratories International Inc Corp (CRL) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of -0.49%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CRL decreased by 0.30% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -91.34 to -110.28.
The secondary factor is the Revenue Growth, contributed -0.49%to the performance.
Overall, the performance of CRL in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Charles River Laboratories International Inc (CRL) currently overvalued or undervalued?
What is Charles River Laboratories International Inc (CRL) fair value?
How does CRL's valuation metrics compare to the industry average?
What is the current P/B ratio for Charles River Laboratories International Inc (CRL) as of Dec 05 2025?
What is the current FCF Yield for Charles River Laboratories International Inc (CRL) as of Dec 05 2025?
What is the current Forward P/E ratio for Charles River Laboratories International Inc (CRL) as of Dec 05 2025?